JLE

Néphrologie & Thérapeutique

MENU

Heart disease in hemodialysis: physiopathology and therapeutic breakthroughs Volume 19, issue 6, October 2023

Authors
1 Hôpitaux Sorbonne Université, sites Pitié-Salpêtrière, Tenon, AP-HP, service de néphrologie, Paris, France
2 Sorbonne Université, INSERM UMR_S 1155, Paris, France
3 Sorbonne Université, ACTION Study Group, INSERM UMRS 1166, Institut de cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
Correspondance : L. Mercadal
lucile.mercadal@aphp.fr

Especially exposed to frequent cardiovascular events and its related mortality, some cardiovascular therapies of the hemodialyzed population as well as coronary investigations remain controversial. We have collected data and discussed recent trials and guidelines dedicated to this patient subset.